Clinical trials
Non-small Lung Cancer clinical trials
Below are recruiting non-small lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,121 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06648317Recruiting
New PET scan for lung tumors using a Nectin-4 probe
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06659042RecruitingPhase 2
Tislelizumab before and after surgery for KRAS-mutated lung cancer
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06660407RecruitingPhase 2
Grid radiation for advanced lung cancer after immunotherapy
This trial tests a special type of radiation called grid therapy for people with stage IV non-small cell lung cancer that has grown after immunotherapy or chemoimmunotherapy. It aims to see if this approach can help control tumors that are larger than 3 centimeters outside the brain.
Rochester, MinnesotaAges 18 years+ - NCT06667154RecruitingPhase 2
Low-dose nivolumab plus chemo for early lung cancer
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
São José do Rio Preto, São PauloAges 18 years+ - NCT06667167RecruitingPhase 2
First-line Keytruda + chemo then Keytruda + Trodelvy for SCLC
This trial tests a two-step treatment for extensive-stage small cell lung cancer: first, chemotherapy combined with Keytruda (an immunotherapy), followed by Keytruda plus Trodelvy (another targeted drug). The goal is to see if this combination helps people live longer and keeps the cancer under control.
Jerusalem, IsraelAges 18–99 - NCT06671613Recruiting
Fasting-mimicking diet with immunotherapy for advanced lung cancer
This study combines a special periodic diet that mimics fasting with the standard immunotherapy drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer. The goal is to see if the diet can help the immunotherapy work better.
Long Beach, CaliforniaAges 18 years+ - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06684418Recruiting
AI to find hidden cancer spread in early lung cancer
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
ShanghaiAges 18 years+ - NCT06687408Recruiting
Minimally invasive sleeve lobectomy for lung cancer
This study looks at a type of lung cancer surgery called sleeve lobectomy done with small incisions (minimally invasive). It aims to see if this approach is safe and effective for people with non-small cell lung cancer that requires removing a part of the lung and reconnecting the airway.
HangzhouAges 18 years+ - NCT06691776Recruiting
Adaptive radiotherapy for five cancer types
This trial tests whether a newer type of daily CT scan (CBCT-guided adaptive radiotherapy) can safely and accurately deliver radiation to cancers of the prostate, cervix, bladder, lung, or head and neck. The goal is to better target the tumor and reduce side effects.
AmsterdamAges 18 years+ - NCT06693336RecruitingPhase 2
Adjuvant chemotherapy trial for early-stage lung cancer
This trial tests a chemotherapy drug called SMS001 (a form of paclitaxel) after surgery for non-small cell lung cancer. It may help prevent the cancer from coming back.
Rochester, MinnesotaAges 18–80 - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06702826RecruitingPhase 2
Cadonilimab plus radiation for lung cancer brain mets
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
Changsha, HunanAges 18–75 - NCT06705465Recruiting
Rehabilitation for lung cancer patients
This trial tests a cross-sector rehabilitation program for people with non-small cell lung cancer (the most common type of lung cancer) who are starting their first cancer treatment. The goal is to see if this program helps you recover and feel better during and after treatment.
Herlev, DenmarkAges 18 years+ - NCT06706713RecruitingPhase 2
Testing BEBT-109 for advanced EGFR exon 20 lung cancer
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT05424029Recruiting
Test blood and lung fluid markers to predict lung cancer return
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
Basking Ridge, New JerseyAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
La Jolla, CaliforniaAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06699979Recruiting
Early lung cancer study with multiple tumors or cysts
This study looks at the genes and molecules of early-stage lung cancer in two groups: people with more than one lung tumor at the same time, and people whose lung cancer is tied to air-filled spaces (cysts) seen on a CT scan. The goal is to better understand these types of lung cancer.
Changsha, HunanAges 18 years+ - NCT07538804RecruitingPhase 1/Phase 2
Testing ANS02 for EGFR-Mutated Lung Cancer
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
Fairfax, VirginiaAges 18 years+ - NCT06780085RecruitingPhase 2
Study of new drugs for advanced lung cancer
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
Lexington, KentuckyAges 18 years+
Hear when a new Non-small Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-small lung cancer?
- Yes. Clin2 currently lists 1,121 recruiting non-small lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-small lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-small lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Lung Cancer, Non-Small Cell
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.